Breaking News, Financial News

Financial Report: Gilead Sciences

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences 1Q Revenues: $1.3 billion (+22%) 1Q Earnings: $496.1 million (+22%) Comments: The company achieved record product sales of $1.1 billion (+36%). HIV product sales were $964.7 million in the quarter (+37%). Truvada sales were $479.4 million (+39%), Atripla sales were $324.2 million (+70%), Viread sales were $152.7 million (-5%). Sales of Hepsera for chronic Hepatitis B, were $83.0 million (+16%). Sales of AmBisome were $71.0 million (+15%). R&D expenses in the quarter...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters